Optimi Health Corp. (C:OPTI)
Business Focus: Health Food Stores
Apr 23, 2024 08:18 am ET
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic...
Apr 15, 2024 08:00 am ET
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three...
Apr 09, 2024 09:13 am ET
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an...
Apr 04, 2024 08:55 am ET
Early Warning Press Release in Accordance with National Instrument 62-103
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer") pursuant to acquisitions in the public market. The Common Shares of the Issuer are listed on the CSE under the trading symbol "OPTI".
Apr 02, 2024 07:30 am ET
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is pleased to announce that three...
Mar 28, 2024 07:30 am ET
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a...
Mar 26, 2024 07:30 am ET
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to announce it has entered...
Feb 28, 2024 07:30 am ET
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, announces that on...
Feb 12, 2024 07:00 am ET
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, extends its...
Feb 08, 2024 07:30 am ET
Optimi Announces Non-Brokered Private Placement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, announces it...
Feb 06, 2024 07:30 am ET
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is announcing an informative webinar...
Jan 19, 2024 07:30 am ET
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to...
Jan 03, 2024 07:30 am ET
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant...
Dec 07, 2023 07:30 am ET
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply...
Nov 28, 2023 07:42 am ET
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of...
Nov 10, 2023 07:30 am ET
Optimi Health Resolves Dispute
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply...
Nov 07, 2023 07:30 am ET
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Canadian psychedelics drug research and formulation company, is delighted to announce the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (“CSO”). Dr....
Nov 02, 2023 07:30 am ET
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade...
Sep 14, 2023 02:59 pm ET
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial...
Sep 07, 2023 07:30 am ET
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers...
Sep 05, 2023 07:30 am ET
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade...
Aug 10, 2023 07:30 am ET
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to...
Aug 01, 2023 07:30 am ET
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets,...
Jul 27, 2023 09:20 am ET
Optimi Health Announces Receipt of Purported Termination Notice
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on...
Jun 15, 2023 09:40 am ET
Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets,...
May 17, 2023 08:15 am ET
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets,...
May 10, 2023 08:45 am ET
Optimi Health Granted Natural Health Product Site Licence By Health Canada
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as...
May 04, 2023 09:00 am ET
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a CAD$1.2 million definitive supply agreement with a private entity focused on developing mushroom-based therapeutic...
Mar 01, 2023 07:30 am ET
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply psychedelic substances such as...
Feb 22, 2023 11:37 am ET
CSE Bulletin: Expiry - Optimi Health Corp. 24FEB2023 Warrants (OPTI.WT)
Toronto, Ontario--(Newsfile Corp. - Le 22 février/February 2023) - Optimi Health Corp. 24FEB2023 Warrants listed on February 25, 2021 will expire on February 24, 2023.
Feb 07, 2023 10:31 am ET
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic...
Feb 06, 2023 08:30 am ET
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under GMP-compliant protocols, making additional MDMA product...
Jan 17, 2023 09:00 am ET
Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP grade psilocybin, synthetic...
Jan 10, 2023 04:15 pm ET
Optimi Health Announces Re-Appointments to Board of Directors
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of...
Oct 11, 2022 09:00 am ET
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading GMP producer and safe supply advocate licensed by Health Canada to produce and distribute natural, EU-GMP grade psilocybin and other psychedelic...
Oct 06, 2022 12:51 pm ET
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably...
Sep 22, 2022 09:00 am ET
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is...
Sep 08, 2022 09:00 am ET
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. The Company is licensed by...
Sep 07, 2022 09:00 am ET
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushroom products for transformational...
Sep 01, 2022 09:00 am ET
Optimi Health Provides Progress Report On Year Of Commercialization
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as...
Aug 30, 2022 09:00 am ET
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human...
Aug 25, 2022 09:00 am ET
Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human...
Aug 16, 2022 09:00 am ET
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human...
Aug 10, 2022 09:00 am ET
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic...
Aug 08, 2022 09:00 am ET
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic...
Jul 13, 2022 09:00 am ET
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational...
Jun 28, 2022 09:00 am ET
Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for...
Jun 20, 2022 09:00 am ET
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request...
Jun 08, 2022 09:00 am ET
Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce...
May 31, 2022 09:00 am ET
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce...
May 27, 2022 09:00 am ET
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce...
May 25, 2022 09:00 am ET
Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an...
May 19, 2022 09:00 am ET
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce...
May 17, 2022 09:00 am ET
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce...
May 11, 2022 09:00 am ET
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility. The on-site...
May 09, 2022 09:00 am ET
Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in...
May 04, 2022 09:00 am ET
Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that a requested Amendment to its Controlled Substances Dealer’s Licence has been granted by Health Canada, enabling it to further expand...
Apr 28, 2022 02:00 pm ET
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members...
Mar 30, 2022 01:00 pm ET
Stocks2Watch to host Optimi Health Investor Day, Tuesday April 5
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Stocks2Watch would like to invite the Investment Community to Optimi Health's Investor Day, Tuesday, April 5 at 1pm (PT) 4pm (ET). Individual investors, institutional investors, advisors, and analysts are invited to register now to attend the presentation.
Mar 18, 2022 09:00 am ET
Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility. “These...
Mar 08, 2022 01:49 pm ET
Optimi Health Announces Investor Relations Agreement
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Mar 01, 2022 09:00 am ET
Optimi Health Upgrades Trading to the OTCQX Best Market
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Mar 01, 2022 07:00 am ET
OTC Markets Group Welcomes Optimi Health Corp. to OTCQX
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Optimi Health Corp. (CSE: OPTI; OTCQX: OPTHF), developers of a vertically integrated mushroom brand targeting functional...
Feb 22, 2022 10:34 am ET
UPDATE - Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Feb 22, 2022 09:00 am ET
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Feb 16, 2022 09:00 am ET
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Feb 07, 2022 09:00 am ET
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Jan 18, 2022 09:00 am ET
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Jan 05, 2022 04:16 pm ET
Optimi Health Provides Dealer License Update and Comments on Health Canada’s Amendments to the Special Access Program (SAP)
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to...
Dec 21, 2021 09:00 am ET
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is...
Dec 07, 2021 09:00 am ET
Optimi Health Requests Final Inspection for Dealer’s License
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is...
Nov 03, 2021 09:00 am ET
Optimi Health Engages Expert Management Consultancy to Drive Corporate Visibility
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is...
Oct 19, 2021 09:00 am ET
Optimi Health Appoints Principal Investigator for Clinical Dosing Study
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is...
Oct 05, 2021 09:00 am ET
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent filing...
Sep 14, 2021 09:00 am ET
Optimi Health Updates Build-Out of Mushroom Production and Research Facility
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to offer an activity update at its 20,000...
Aug 31, 2021 09:00 am ET
Optimi Health Appoints New Chief Executive Officer
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that William (Bill) J. Ciprick...
Aug 18, 2021 09:00 am ET
Optimi Health Clears Final Base Shelf Prospectus
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed and received a...
Aug 10, 2021 09:00 am ET
Optimi Health Updates Launch of Online Functional Mushroom Sales
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, announced today that preparations for a fourth quarter...
Jul 27, 2021 09:00 am ET
Optimi Health Strengthens Clinical and Regulatory Expertise
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate...
Jul 13, 2021 09:00 am ET
Optimi Health Joins First Psychedelic Exchange Traded Fund
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The...
Jul 07, 2021 09:00 am ET
Optimi Health Initiates Pathway to Nasdaq Listing
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (“Donohoe...
Jun 29, 2021 09:00 am ET
Optimi Health Supports Patient-Focused Psilocybin Advocacy by TheraPsil
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products, is pleased to announce it has initiated corporate support as one of TheraPsil’s first Core Spore Supporters...
Jun 23, 2021 09:00 am ET
Optimi Health Engages U.S. Based Law Firm for Patent Support
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products today announced that Thomas Finetti, partner at Charney IP Law, has been engaged to oversee ongoing patent...
Jun 17, 2021 09:00 am ET
Optimi Health Completes OTC Markets Uplisting to OTCQB
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated mushroom product developer wishes to advise it has successfully concluded uplisting to the OTCQB exchange operated by OTC Markets Group...
Jun 15, 2021 09:00 am ET
Optimi Health Completes Pre-Clinical Trial Application Meeting
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated mushroom product developer and research partners with Numinus Wellness Inc., a mental health care company advancing innovative treatments...
Jun 08, 2021 09:00 am ET
Optimi Health Announces Product Distribution Agreement with Vitasave
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has entered into a...
Jun 03, 2021 09:00 am ET
Optimi Health Announces DTC Eligibility & Up-List to OTCQB
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets...
May 26, 2021 09:00 am ET
Optimi Health Appoints Chief Science Officer
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the engagement of Mr. Justin D....
May 11, 2021 09:00 am ET
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a...
May 04, 2021 09:00 am ET
Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its previously announced lab...
Apr 27, 2021 09:00 am ET
Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to offer an activity update at its 20,000 sq....
Apr 14, 2021 09:00 am ET
Optimi Health Adds to Corporate and Advisory Team
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the appointments of Dr. Azim...
Apr 06, 2021 09:30 am ET
Optimi Health Aims to Expand its Shareholder Base
Optimi Health Corp. (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the addition of their overseas listing. The...
Mar 23, 2021 09:00 am ET
Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and Licensing
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to provide the following overview and update of its facility...
Mar 16, 2021 09:00 am ET
Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce it has received product licensing paving the way for the...
Mar 09, 2021 09:00 am ET
Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce a service agreement with the IMPACT Clinical Trial...
Mar 02, 2021 09:00 am ET
OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab...
Feb 25, 2021 09:00 am ET
Optimi Health Corp. Completes Oversubscribed $20.7 Million Initial Public Offering, and Announces Listing on the CSE
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the closing of its oversubscribed initial public offering...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
